These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34260044)

  • 1. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials.
    Warren RB; Gottlieb AB; Merola JF; Garcia L; Cioffi C; Peterson L; Pelligra C; Ciaravino V
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1551-1569. PubMed ID: 34260044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.
    Gottlieb AB; Warren RB; Augustin M; Garcia L; Cioffi C; Peterson L; Pelligra C; Ciaravino V
    Adv Ther; 2021 Oct; 38(10):5253-5269. PubMed ID: 34471992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study.
    Asahina A; Okubo Y; Morita A; Tada Y; Igarashi A; Langley RG; Deherder D; Matano M; Vanvoorden V; Wang M; Ohtsuki M; Nakagawa H
    Dermatol Ther (Heidelb); 2023 Mar; 13(3):751-768. PubMed ID: 36648594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
    Viswanathan HN; Mutebi A; Milmont CE; Gordon K; Wilson H; Zhang H; Klekotka PA; Revicki DA; Augustin M; Kricorian G; Nirula A; Strober B
    Value Health; 2017 Sep; 20(8):1174-1179. PubMed ID: 28964451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis.
    Gottlieb AB; Ciaravino V; Cioffi C; Peterson L; Warren RB
    Dermatol Ther (Heidelb); 2020 Dec; 10(6):1255-1272. PubMed ID: 32844372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.
    Strober B; Zhao Y; Tran MH; Gnanasakthy A; Nyirady J; Papavassilis C; Nelson LM; McLeod LD; Mordin M; Gottlieb AB; Elewski BE; Lebwohl M
    Int J Dermatol; 2016 Mar; 55(3):e147-55. PubMed ID: 26518255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial.
    Armstrong A; Puig L; Langley R; Tsai TF; Song M; Wasfi Y; Jiang J; Li S; Han C
    J Dermatolog Treat; 2019 Feb; 30(1):27-34. PubMed ID: 28797188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis.
    Rentz AM; Skalicky AM; Esser D; Zema C; Becker K; Bodhani A; Revicki DA
    J Dermatolog Treat; 2020 Aug; 31(5):460-469. PubMed ID: 32045314
    [No Abstract]   [Full Text] [Related]  

  • 9. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis.
    Kimball AB; Naegeli AN; Edson-Heredia E; Lin CY; Gaich C; Nikaï E; Wyrwich K; Yosipovitch G
    Br J Dermatol; 2016 Jul; 175(1):157-62. PubMed ID: 26852717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis.
    Gwaltney C; Ivanescu C; Karlsson L; Warholic N; Kjems L; Horn P
    Adv Ther; 2022 Nov; 39(11):5105-5125. PubMed ID: 36066745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement properties of the patient global assessment numerical rating scale in moderate-to-severe psoriasis.
    Yu N; Peng C; Zhou J; Gu J; Xu J; Li X; Bi X; Deng H; Li X; Ding Y; Shi Y
    Br J Dermatol; 2023 Sep; 189(4):437-446. PubMed ID: 37310289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Item-level psychometric properties for a new patient-reported psoriasis symptom diary.
    Strober BE; Nyirady J; Mallya UG; Guettner A; Papavassilis C; Gottlieb AB; Elewski BE; Turner-Bowker DM; Shields AL; Gwaltney CJ; Lebwohl M
    Value Health; 2013; 16(6):1014-22. PubMed ID: 24041351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI).
    Burden AD; Bissonnette R; Lebwohl MG; Gloede T; Anatchkova M; Budhiarso I; Hu N; Thoma C; Skalicky AM; Bachelez H
    J Eur Acad Dermatol Venereol; 2023 Jul; 37(7):1327-1335. PubMed ID: 36854864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis.
    Gossec L; Orbai AM; Coates LC; Gladman DD; Ogdie A; Pelligra CG; Ciaravino V; Ink B; Taieb V; Lambert J; de Wit M
    RMD Open; 2024 Jan; 10(1):. PubMed ID: 38296802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
    Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
    N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.